HOUSE_OVERSIGHT_024663.jpg
1.81 MB
Extraction Summary
0
People
4
Organizations
0
Locations
0
Events
0
Relationships
3
Quotes
Document Information
Type:
Investment report / industry analysis
File Size:
1.81 MB
Summary
This document is page 27 of a 2017 report by Ackrell Capital titled 'Cannabis Science 101'. It details the THC/CBD formulation spectrum and lists medical conditions treated by different ratios (e.g., Alzheimer's, Cancer, Anxiety). The text explains the 'entourage effect,' the role of terpenes like Myrcene, and the concept of 'Frankensteining' in cannabis formulations. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024663', indicating it was part of a document production for a congressional investigation.
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC | ||
| FINRA | ||
| SIPC | ||
| House Oversight Committee |
Key Quotes (3)
"The 'entourage effect' refers to the overall user experience produced by the interactions among all active compounds in the cannabis plant."Source
HOUSE_OVERSIGHT_024663.jpg
Quote #1
"Many cannabinoid and terpene formulations developed for therapeutic applications are created by combining extracts from multiple cannabis strains, a process known as 'Frankensteining.'"Source
HOUSE_OVERSIGHT_024663.jpg
Quote #2
"CBD is believed to regulate the psychoactive effects of THC and reduce short-term memory loss, sleepiness and paranoia that may be caused by THC."Source
HOUSE_OVERSIGHT_024663.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (2,666 characters)
ACKRELL
CAPITAL
CHAPTER II Cannabis Science 101
CAPITAL
CHAPTER II Cannabis Science 101
THC and CBD Formulation Spectrum
THC Dominant
Balanced
CBD Dominant
Balanced
CBD Dominant
THC:CBD 25:1 to 100:1
THC:CBD 10:1 to 25:1
THC:CBD 5:1 to 10:1
THC:CBD 4:1
THC:CBD 1:4
THC:CBD 1:5 to 1:10
THC:CBD 1:10 to 1:25
THC:CBD 1:25 to 1:100
THC:CBD 10:1 to 25:1
THC:CBD 5:1 to 10:1
THC:CBD 4:1
THC:CBD 1:4
THC:CBD 1:5 to 1:10
THC:CBD 1:10 to 1:25
THC:CBD 1:25 to 1:100
THC Level
CBD Level
CBD Level
[Blue Box List]
• Alzheimer's disease
• Anorexia
• Appetite stimulant
• Chronic pain
• Alzheimer's disease
• Anorexia
• Appetite stimulant
• Chronic pain
[Green Box List]
• Amyotrophic lateral sclerosis (ALS)
• Cachexia
• Cancer
• Glaucoma
• Hepatitis C
• HIV/AIDS
• Migraine
• Multiple sclerosis
• Nausea
• Spasms
• Amyotrophic lateral sclerosis (ALS)
• Cachexia
• Cancer
• Glaucoma
• Hepatitis C
• HIV/AIDS
• Migraine
• Multiple sclerosis
• Nausea
• Spasms
[Orange Box List]
• Anxiety
• Epilepsy
• Depression
• Inflammation
• Nervous system degeneration
• Parkinson's disease
• Post-traumatic stress disorder (PTSD)
• Anxiety
• Epilepsy
• Depression
• Inflammation
• Nervous system degeneration
• Parkinson's disease
• Post-traumatic stress disorder (PTSD)
The “entourage effect” refers to the overall user experience produced by the interactions among all active compounds in the cannabis plant. The various cannabinoids and terpenes in a particular cannabis plant are believed to work synergistically with each other and with the human endocannabinoid system to create an effect very different from the effect any one compound would create. This phenomenon may partially explain why different cannabis strains are used to treat diverse medical conditions.
There are several generally accepted examples of the entourage effect. CBD is believed to regulate the psychoactive effects of THC and reduce short-term memory loss, sleepiness and paranoia that may be caused by THC. Myrcene is understood to enable and hasten the psychoactive effect of THC by lowering resistance posed by the blood-brain barrier and increasing the THC saturation capacity of the CB1 receptors. Other terpenes have been shown to block endocannabinoid receptors in the brain while promoting bonding by endocannabinoid receptors located elsewhere in the body.
Many cannabinoid and terpene formulations developed for therapeutic applications are created by combining extracts from multiple cannabis strains, a process known as “Frankensteining.” Some believe Frankenstein formulations are less effective than formulations developed from a single strain because the natural balance of compounds in a single strain translates to a naturally balanced effect on the human body.
An understanding of entourage effects and how to effectively combine cannabinoids and terpenes is believed to be critical to the development of targeted cannabis therapies. Examples of cannabis-based therapies being developed with specific cannabinoid-terpene profiles include acne medication containing CBD and limonene, linalool and pinene; antiseptic agents containing CBG and pinene; treatments
© 2017 Ackrell Capital, LLC | Member FINRA / SIPC
27
HOUSE_OVERSIGHT_024663
27
HOUSE_OVERSIGHT_024663
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document